{ "@context": "https://clearank.com/llms.txt", "@type": "clearank:AssetAnalysis", "url": "https://clearank.com/stock/bdx-stock-analysis/", "dataUrl": "https://clearank.com/stock/bdx-stock-analysis/data.json", "title": "Becton, Dickinson and Company (BDX) Stock Forecast (2026)", "description": "Is Becton Dickinson (BDX) a Buy or Sell today? Get the AI trade setup, key support levels, valuation and risk analysis. Updated daily.", "headline": "Becton, Dickinson and Company (BDX)", "published": "2026-09-05T09:25:18+00:00", "modified": "2026-09-11T00:12:04.385+00:00", "generated": "2026-09-11T21:36:56.057Z", "language": "en-US", "publisher": { "name": "CleaRank", "url": "https://clearank.com/" }, "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.", "asset": { "ticker": "BDX", "name": "Becton, Dickinson and Company", "type": "Common Stock", "exchange": "NYSE", "currency": "USD", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "country": "United States", "website": "https://www.bd.com" }, "quote": { "price": 176.42, "previousClose": 179.8, "change": -3.38, "changePercent": -1.88, "open": 178.94, "high": 178.94, "low": 175.67, "volume": 1679979, "averageVolume": 1608988, "marketCap": 48054479256, "fiftyTwoWeekHigh": 193.070007, "fiftyTwoWeekLow": 127.58648, "marketOpen": false, "asOf": "2026-09-11T00:12:03.000Z" }, "statistics": { "pe": 30.986158, "eps": 5.78, "dividendYield": 0.023805476247557193, "beta": 0.276, "priceToSales": 2.169742, "priceToBook": 1.9980589, "revenueTtm": 22484000768, "grossMargin": 0.46457957053983545, "returnOnEquity": 0.06607 }, "technicals": { "rsi": 28.46, "macd": 2.39, "sma50": 171.46, "sma200": 160.22, "rsiSignal": "Oversold", "trend": "Bullish", "pricePosition": "Bullish", "macdSignal": "Bullish", "rating": "Bullish" }, "analysis": { "rating": "Hold", "score": 59, "consensus": "Hold", "fairValue": 197.5, "analystTarget": 197.5, "analystCount": 14, "wallStreetConsensus": "Hold", "generatedAt": "2026-09-11T00:12:03.000Z", "priceAtAnalysis": 176.42, "volatility": { "daily": 1.51, "risk": "standard" } }, "tradePlan": { "bias": "Neutral", "conservativeEntry": 174.66, "aggressiveEntry": 176.42, "stopLoss": 168.89, "stopLossPercent": 3.3, "targets": [ 179.9, 183.39, 188.63 ] }, "projections": { "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets", "years": [ { "year": 2027, "downside10th": 135.79, "base": 184.94, "upside90th": 251.89 }, { "year": 2028, "downside10th": 125.25, "base": 193.88, "upside90th": 300.11 }, { "year": 2029, "downside10th": 119.02, "base": 203.24, "upside90th": 347.07 }, { "year": 2030, "downside10th": 114.86, "base": 213.06, "upside90th": 395.24 }, { "year": 2031, "downside10th": 111.93, "base": 223.35, "upside90th": 445.68 }, { "year": 2032, "downside10th": 109.85, "base": 234.14, "upside90th": 499.06 }, { "year": 2033, "downside10th": 108.39, "base": 245.46, "upside90th": 555.87 }, { "year": 2034, "downside10th": 107.39, "base": 257.31, "upside90th": 616.56 }, { "year": 2035, "downside10th": 106.76, "base": 269.74, "upside90th": 681.53 }, { "year": 2036, "downside10th": 106.45, "base": 282.77, "upside90th": 751.18 } ] }, "faqCount": 7, "sources": [ "TwelveData", "Wall Street consensus" ], "sections": [ { "id": "price", "title": "BDX Price Analysis" }, { "id": "market-metrics", "title": "Market Metrics", "facts": { "Open": "$178.94", "Day Range": "$175.67 to $178.94", "Prev Close": "$179.80", "Volume": "1.68M", "52-Week Range": "$127.59 to $193.07", "Market Cap": "$48.05B" } }, { "id": "peer-benchmarking", "title": "Peer Benchmarking", "text": [ "Sector Position Analysis Valuation is broadly in line with sector peers (-0.0124% difference), suggesting fair market pricing relative to industry standards." ] }, { "id": "analysis", "title": "BDX Analysis", "text": [ "Becton, Dickinson and Company (BDX) is trading above its 50-day and 200-day moving averages ($171.46 and $160.22), indicating a generally positive long-term trend, but is currently below its 20-day EMA, suggesting near-term weakness. The Relative Strength Index (RSI) is at 28.46, signaling oversold conditions that could precede a bounce. MACD is positive at 2.39, but the overall chart structure, combined with moderate insider selling, warrants caution despite the oversold technicals.", "Becton, Dickinson and Company (BDX) beat EPS estimates in the latest reported quarter (August 2026) by 2.87%, indicating operational resilience.", "Insiders have sold a net $3.2 million more stock than they purchased in recent transactions, signaling a potential lack of confidence in near-term price appreciation.", "Current quarter revenue estimates show a projected year-over-year decline of 13.00%, posing a risk to future profitability and valuation.", "The stock is trading above its 50-day and 200-day moving averages ($171.46 and $160.22), indicating some underlying support, though it is currently below its 20-day EMA.", "However, the current revenue decline and moderate insider selling present significant headwinds that could limit upside potential in the near to medium term. Investors should monitor upcoming earnings reports and revenue trends closely. Insiders are net sellers with $111.9M in total sales versus $1.4M in total purchases in recent filings." ], "lists": { "ProTips": [ "Given the moderate insider selling and declining revenue growth, consider a cautious approach to new positions in Becton, Dickinson and Company (BDX) until a clear turnaround in sales is evident.", "The stock's RSI is in oversold territory, suggesting a potential short-term bounce could occur, but this should be viewed with caution given the fundamental headwinds.", "With a dividend yield of 2.12%, Becton, Dickinson and Company (BDX) offers a modest income stream, but investors should prioritize the company's ability to reverse its revenue decline." ] }, "catalysts": [ { "type": "Bullish", "title": "Recent Earnings Beat", "text": "Becton, Dickinson and Company (BDX) beat EPS estimates in the latest reported quarter (August 2026) by 2.87%, indicating operational resilience.", "source": "Earnings Report" }, { "type": "Bearish", "title": "Moderate Insider Selling", "text": "Insiders have sold a net $3.2 million more stock than they purchased in recent transactions, signaling a potential lack of confidence in near-term price appreciation.", "source": "Insider Transactions" }, { "type": "Bearish", "title": "Declining Revenue Growth", "text": "Current quarter revenue estimates show a projected year-over-year decline of 13.00%, posing a risk to future profitability and valuation.", "source": "Wall Street Estimates" }, { "type": "Neutral", "title": "Trading Above Key Moving Averages", "text": "The stock is trading above its 50-day and 200-day moving averages ($171.46 and $160.22), indicating some underlying support, though it is currently below its 20-day EMA.", "source": "Technical Analysis" } ] }, { "id": "key-statistics", "title": "Key Statistics", "text": [ "Becton, Dickinson and Company (BDX) exhibits a P/E ratio of 30.99, which is in line with the sector average of 30.99, suggesting fair valuation relative to peers. However, the company is experiencing a revenue growth slowdown, with current quarter estimates showing a 13.00% year-over-year decline. While the company has a healthy balance sheet and profitability metrics are generally stable, the declining revenue trend is a concern that tempers the attractiveness of its current valuation.", "Becton, Dickinson and Company (BDX) recently reported earnings that beat estimates, with EPS of $3.23 against an estimate of $3.14 for the August 2026 quarter, a 2.87% surprise. However, this positive earnings surprise did not translate into significant stock price appreciation, with a -0.12% change. The company has a history of beating estimates, but the recent revenue growth has turned negative, indicating potential challenges ahead.", "A primary risk for Becton, Dickinson and Company (BDX) is the moderate insider selling, with total sales exceeding purchases by over $3 million, signaling potential concerns among management. Additionally, the company is facing a significant revenue growth slowdown, with current quarter estimates projecting a 13.00% year-over-year decline, which could pressure future earnings and valuation." ], "tables": [ { "caption": "", "columns": [], "rows": [ { "label": "Market Cap", "cells": [ "48.05B" ] }, { "label": "P/E Ratio", "cells": [ "30.99" ] }, { "label": "EPS (TTM)", "cells": [ "5.78" ] }, { "label": "Dividend Yield", "cells": [ "2.12%" ] }, { "label": "52 Week High", "cells": [ "193.07" ] }, { "label": "52 Week Low", "cells": [ "127.59" ] } ] } ] }, { "id": "technical-indicators", "title": "Technical Indicators", "text": [ "Technical Rating Bullish RSI Oversold SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($171.46) above the 200-day SMA ($160.22), price action is firmly bullish above key moving averages, RSI at 28.5 suggests oversold conditions; potential bounce setup." ], "facts": { "RSI": "Oversold", "SMA Cross": "Bullish", "Price vs SMA": "Bullish", "MACD": "Bullish" }, "tables": [ { "caption": "", "columns": [], "rows": [ { "label": "RSI (14)", "cells": [ "28.46" ] }, { "label": "MACD", "cells": [ "2.39" ] }, { "label": "SMA 50", "cells": [ "171.46" ] }, { "label": "SMA 200", "cells": [ "160.22" ] } ] } ] }, { "id": "correlations", "title": "Market Correlations", "text": [ "How this stock moves relative to other assets", "Based on 1 year of daily price data. Correlations may vary over different time periods." ], "facts": { "Correlation with S&P 500 (SPY)": "+0.26", "Correlation with Nasdaq 100 (QQQ)": "+0.12", "Correlation with Bitcoin (BTC)": "-0.02", "Correlation with Gold (XAU)": "+0.09" } }, { "id": "trade-plans", "title": "BDX Trade Plans", "text": [ "Specific entry, exit, and risk management levels", "Enter now if confident", "Volatility-Adjusted Stop Loss Calculated based on RSI (28.5) and current market volatility", "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3" ], "facts": { "TARGET 1": "$179.90", "TARGET 2": "$183.39", "TARGET 3": "$188.63", "STOP LOSS": "$168.89" } }, { "id": "risk", "title": "Risk & Volatility", "facts": { "Daily Volatility": "1.51%" }, "lists": { "Risk considerations": [ "Monitor position sizing based on current volatility levels", "Consider stop-loss placement beyond recent price range", "Diversification helps mitigate single-stock risk exposure" ] } }, { "id": "growth", "title": "Growth of $10,000", "text": [ "A $10,000 investment in BDX in September 2016 would be worth about $13,274 today, compared with about $35,030 for the same investment in the S&P 500 benchmark." ] }, { "id": "monte-carlo", "title": "Monte Carlo Projection (10yr)", "text": [ "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in BDX today could grow to about $16,028 by 2036 in the base case, with a bull case near $42,579 and a bear case around $6,034. Projections are statistical simulations, not guarantees." ] }, { "id": "price-prediction", "title": "BDX Stock Price Prediction: 2030", "text": [ "CleaRank's simulation projects a price near $213 for BDX by 2030 in the base case, from $176 today (1.2x over 4 years). The downside path ends near $115. These are outcomes of a Monte Carlo simulation run on BDX's historical return distribution, not price targets, and they assume no dividends are reinvested.", "Method: 10,000 simulated price paths using BDX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice." ], "tables": [ { "caption": "BDX simulated price paths by year", "columns": [ "Year", "Downside (10th pct)", "Base case", "Upside (90th pct)" ], "rows": [ { "label": "2027", "cells": [ "$136", "$185", "$252" ] }, { "label": "2028", "cells": [ "$125", "$194", "$300" ] }, { "label": "2029", "cells": [ "$119", "$203", "$347" ] }, { "label": "2030", "cells": [ "$115", "$213", "$395" ] }, { "label": "2031", "cells": [ "$112", "$223", "$446" ] }, { "label": "2032", "cells": [ "$110", "$234", "$499" ] }, { "label": "2033", "cells": [ "$108", "$245", "$556" ] }, { "label": "2034", "cells": [ "$107", "$257", "$617" ] }, { "label": "2035", "cells": [ "$107", "$270", "$682" ] }, { "label": "2036", "cells": [ "$106", "$283", "$751" ] } ] } ] }, { "id": "people-also-watch", "title": "People Also Watch", "links": [ { "text": "ISRG Intuitive Surgical Inc. NASDAQ $358.08 +1.37%", "url": "https://clearank.com/stock/intuitive-surgical-isrg/" }, { "text": "VEEV Veeva Systems Inc. NYSE $262.25 +0.4866%", "url": "https://clearank.com/stock/veev-stock-analysis/" }, { "text": "MDT Medtronic NYSE $90.78 -0.9223%", "url": "https://clearank.com/stock/medtronic-mdt/" }, { "text": "MOH Molina Healthcare Inc. NYSE $200.28 +3.17%", "url": "https://clearank.com/stock/moh-stock-analysis/" }, { "text": "LEGN Legend Biotech Corporation NASDAQ $19.91 -2.83%", "url": "https://clearank.com/stock/legend-biotech-legn/" }, { "text": "JNJ Johnson & Johnson NYSE $265.63 -0.2703%", "url": "https://clearank.com/stock/johnson-johnson-jnj/" }, { "text": "VKTX Viking Therapeutics, Inc. NASDAQ $32.13 -1.74%", "url": "https://clearank.com/stock/viking-therapeutics-vktx/" }, { "text": "ILMN Illumina Inc. NASDAQ $206.28 +2.49%", "url": "https://clearank.com/stock/ilmn-stock-analysis/" } ] }, { "id": "related-comparisons", "title": "Popular Comparisons", "links": [ { "text": "XOM vs CVX Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/xom-vs-cvx/" }, { "text": "XAU/USD vs XPT/USD Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/gold-vs-platinum/" }, { "text": "RIVN vs LCID Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/rivn-vs-lcid/" } ] }, { "id": "insider-trading", "title": "BDX Insider Trading Analysis", "facts": { "Bought": "$1.0M", "Sold": "$4.2M", "Insiders": "26", "Avg Transaction": "$172.7K" }, "tables": [ { "caption": "Recent insider transactions in BDX", "columns": [ "Date", "Insider", "Type", "Shares", "Value" ], "rows": [ { "label": "Jan 27, 2020", "cells": [ "FORLENZA VINCENT A Chief Executive Officer", "Sell", "39.0K", "$10.9M" ] }, { "label": "Jan 10, 2020", "cells": [ "FORLENZA VINCENT A Chief Executive Officer", "Sell", "33.5K", "$9.2M" ] }, { "label": "Jan 2, 2020", "cells": [ "FORLENZA VINCENT A Chief Executive Officer", "Sell", "33.4K", "$9.1M" ] }, { "label": "Jan 28, 2020", "cells": [ "FORLENZA VINCENT A Chief Executive Officer", "Sell", "28.5K", "$8.0M" ] }, { "label": "Aug 9, 2019", "cells": [ "LIM JAMES C Officer", "Sell", "23.9K", "$6.0M" ] }, { "label": "Aug 9, 2022", "cells": [ "KHICHI SAMRAT S General Counsel", "Sell", "16.5K", "$4.3M" ] }, { "label": "Feb 25, 2022", "cells": [ "LARSON BETTY D Officer", "Sell", "14.4K", "$3.9M" ] }, { "label": "May 21, 2019", "cells": [ "KHICHI SAMRAT S General Counsel", "Sell", "16.1K", "$3.8M" ] }, { "label": "Dec 16, 2019", "cells": [ "MAS RIBO ALBERTO Officer", "Sell", "11.9K", "$3.2M" ] }, { "label": "Dec 12, 2019", "cells": [ "FORLENZA VINCENT A Chief Executive Officer", "Sell", "11.6K", "$3.1M" ] } ] } ], "links": [ { "text": "SEC Form 4", "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Becton%2C+Dickinson+and+Company&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany" } ] }, { "id": "faq", "title": "Frequently Asked Questions" } ], "faq": [ { "question": "What is Becton, Dickinson and Company's (BDX) current consensus rating?", "answer": "Becton, Dickinson and Company (BDX) currently holds a 'Hold' consensus rating from Wall Street analysts. This is based on a breakdown of 1 Strong Buy, 6 Buy, and 7 Hold ratings among the 14 analysts covering the stock." }, { "question": "What is the upside potential for Becton, Dickinson and Company (BDX) stock based on analyst targets?", "answer": "The median analyst price target for Becton, Dickinson and Company (BDX) is $197.50, suggesting an upside potential of 11.9% from its current price of $176.42." }, { "question": "Are Becton, Dickinson and Company (BDX) insiders buying or selling stock?", "answer": "Insiders at Becton, Dickinson and Company (BDX) are net sellers of the stock. Total insider sales amounted to $4.2 million, while total purchases were $1 million, resulting in a moderate sell signal." }, { "question": "What are the key risks facing Becton, Dickinson and Company (BDX)?", "answer": "Key risks for Becton, Dickinson and Company (BDX) include moderate insider selling and a significant slowdown in revenue growth, with current quarter estimates showing a 13.00% year-over-year decline. These factors could impact future profitability and stock performance." }, { "question": "How is Becton, Dickinson and Company (BDX) performing technically?", "answer": "Technically, Becton, Dickinson and Company (BDX) shows oversold conditions with an RSI at 28.5, and is trading above its 50-day and 200-day moving averages ($171.46 and $160.22). However, it is currently below its 20-day EMA, indicating some near-term weakness." }, { "question": "What is the revenue growth outlook for Becton, Dickinson and Company (BDX)?", "answer": "The revenue growth outlook for Becton, Dickinson and Company (BDX) is currently challenged, with current quarter estimates projecting a 13.00% year-over-year decline. The next year's growth is estimated at a modest +2.00%." }, { "question": "Is Becton, Dickinson and Company (BDX) stock a buy right now?", "answer": "Becton, Dickinson and Company (BDX) is currently rated a 'Hold' by Wall Street analysts, with a median price target of $197.50, implying an 11.9% upside. While technically oversold, concerns around revenue slowdown and insider selling suggest caution." } ], "related": { "peopleAlsoWatch": [ { "ticker": "ISRG", "name": "Intuitive Surgical Inc. NASDAQ", "price": "$358.08", "change": "+1.37%", "url": "https://clearank.com/stock/intuitive-surgical-isrg/" }, { "ticker": "VEEV", "name": "Veeva Systems Inc. NYSE", "price": "$262.25", "change": "+0.4866%", "url": "https://clearank.com/stock/veev-stock-analysis/" }, { "ticker": "MDT", "name": "Medtronic NYSE", "price": "$90.78", "change": "-0.9223%", "url": "https://clearank.com/stock/medtronic-mdt/" }, { "ticker": "MOH", "name": "Molina Healthcare Inc. NYSE", "price": "$200.28", "change": "+3.17%", "url": "https://clearank.com/stock/moh-stock-analysis/" }, { "ticker": "LEGN", "name": "Legend Biotech Corporation NASDAQ", "price": "$19.91", "change": "-2.83%", "url": "https://clearank.com/stock/legend-biotech-legn/" }, { "ticker": "JNJ", "name": "Johnson & Johnson NYSE", "price": "$265.63", "change": "-0.2703%", "url": "https://clearank.com/stock/johnson-johnson-jnj/" }, { "ticker": "VKTX", "name": "Viking Therapeutics, Inc. NASDAQ", "price": "$32.13", "change": "-1.74%", "url": "https://clearank.com/stock/viking-therapeutics-vktx/" }, { "ticker": "ILMN", "name": "Illumina Inc. NASDAQ", "price": "$206.28", "change": "+2.49%", "url": "https://clearank.com/stock/ilmn-stock-analysis/" } ], "comparisons": [ { "ticker": "XOM vs CVX Comparison", "name": "", "url": "https://clearank.com/compare/xom-vs-cvx/" }, { "ticker": "XAU/USD vs XPT/USD Comparison", "name": "", "url": "https://clearank.com/compare/gold-vs-platinum/" }, { "ticker": "RIVN vs LCID Comparison", "name": "", "url": "https://clearank.com/compare/rivn-vs-lcid/" } ], "sectorHub": { "text": "Browse all Healthcare →", "url": "https://clearank.com/sector/healthcare/" }, "Newly Tracked": [ { "ticker": "ILMN", "text": "Illumina Inc.", "url": "https://clearank.com/stock/ilmn-stock-analysis/" }, { "ticker": "SLVR", "text": "Sprott Silver Miners & Physical Silver ETF", "url": "https://clearank.com/etf/slvr-etf-analysis/" }, { "ticker": "NTES", "text": "NetEase, Inc.", "url": "https://clearank.com/stock/ntes-stock-analysis/" }, { "ticker": "PCAR", "text": "PACCAR Inc.", "url": "https://clearank.com/stock/pcar-stock-analysis/" }, { "ticker": "O", "text": "Realty Income Corp.", "url": "https://clearank.com/stock/o-stock-analysis/" } ], "Top Movers (24h)": [ { "ticker": "SOXL", "text": "↓ 8.03%", "url": "https://clearank.com/etf/direxion-semiconductor-bull-soxl/" }, { "ticker": "NEAR/USD", "text": "↑ 18.46%", "url": "https://clearank.com/crypto/near-protocol-near-usd/" }, { "ticker": "THETA/USD", "text": "↑ 15.25%", "url": "https://clearank.com/crypto/theta-network-theta-usd/" }, { "ticker": "XHLD", "text": "↑ 15.04%", "url": "https://clearank.com/stock/xhld-stock-analysis/" }, { "ticker": "HPE", "text": "↑ 10.41%", "url": "https://clearank.com/stock/hewlett-packard-enterprise-hpe/" } ], "Also in Healthcare": [ { "ticker": "AMGN", "text": "Amgen", "url": "https://clearank.com/stock/amgen-amgn/" }, { "ticker": "BIIB", "text": "Biogen Inc.", "url": "https://clearank.com/stock/biib-stock-analysis/" }, { "ticker": "ISRG", "text": "Intuitive Surgical", "url": "https://clearank.com/stock/intuitive-surgical-isrg/" }, { "ticker": "RMD", "text": "ResMed", "url": "https://clearank.com/stock/rmd-stock-analysis/" }, { "ticker": "WST", "text": "West", "url": "https://clearank.com/stock/wst-stock-analysis/" } ] }, "schema": [ { "@context": "https://schema.org", "@graph": [ { "@type": "Place", "@id": "https://clearank.com/#place", "address": { "@type": "PostalAddress", "streetAddress": "Beni Berman 2", "addressLocality": "Netanya", "addressRegion": "Center", "postalCode": "4249330", "addressCountry": "IL" } }, { "@type": "Organization", "@id": "https://clearank.com/#organization", "name": "CleaRank", "url": "https://clearank.com", "sameAs": [ "https://twitter.com/CleaRank", "https://www.linkedin.com/company/clearank/", "https://www.youtube.com/@CleaRank" ], "email": "info@clearank.com", "address": { "@type": "PostalAddress", "streetAddress": "Beni Berman 2", "addressLocality": "Netanya", "addressRegion": "Center", "postalCode": "4249330", "addressCountry": "IL" }, "logo": { "@type": "ImageObject", "@id": "https://clearank.com/#logo", "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg", "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg", "caption": "CleaRank", "inLanguage": "en-US", "width": "336", "height": "153" }, "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise", "numberOfEmployees": { "@type": "QuantitativeValue", "value": "40" }, "location": { "@id": "https://clearank.com/#place" } }, { "@type": "WebSite", "@id": "https://clearank.com/#website", "url": "https://clearank.com", "name": "CleaRank", "publisher": { "@id": "https://clearank.com/#organization" }, "inLanguage": "en-US" }, { "@type": "ImageObject", "@id": "https://clearank.com/wp-content/uploads/2026/09/bdx-stock-analysis-2026-09.png", "url": "https://clearank.com/wp-content/uploads/2026/09/bdx-stock-analysis-2026-09.png", "width": "1280", "height": "720", "caption": "Becton Dickinson (BDX) stock price analysis chart for September 2026", "inLanguage": "en-US" }, { "@type": "BreadcrumbList", "@id": "https://clearank.com/stock/bdx-stock-analysis/#breadcrumb", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://clearank.com", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://clearank.com/stock/bdx-stock-analysis/", "name": "Becton, Dickinson and Company (BDX) Stock Analysis" } } ] }, { "@type": "WebPage", "@id": "https://clearank.com/stock/bdx-stock-analysis/#webpage", "url": "https://clearank.com/stock/bdx-stock-analysis/", "name": "Becton, Dickinson and Company (BDX) Stock Forecast (2026)", "datePublished": "2026-09-05T09:25:18+00:00", "dateModified": "2026-09-11T00:12:04+00:00", "isPartOf": { "@id": "https://clearank.com/#website" }, "primaryImageOfPage": { "@id": "https://clearank.com/wp-content/uploads/2026/09/bdx-stock-analysis-2026-09.png" }, "inLanguage": "en-US", "breadcrumb": { "@id": "https://clearank.com/stock/bdx-stock-analysis/#breadcrumb" } }, { "@type": "Organization", "@id": "https://clearank.com/writer/clearank/", "name": "CleaRank", "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.", "url": "https://clearank.com/writer/clearank/", "image": { "@type": "ImageObject", "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g", "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g", "caption": "CleaRank", "inLanguage": "en-US" }, "sameAs": [ "https://clearank.com/", "https://twitter.com/CleaRank", "https://www.linkedin.com/company/clearank/", "https://www.youtube.com/@CleaRank" ], "worksFor": { "@id": "https://clearank.com/#organization" }, "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg" }, { "@type": "Article", "headline": "Becton, Dickinson and Company (BDX) Stock Forecast (2026)", "datePublished": "2026-09-05T09:25:18+00:00", "dateModified": "2026-09-11T00:12:04+00:00", "author": { "@id": "https://clearank.com/writer/clearank/", "name": "CleaRank" }, "publisher": { "@id": "https://clearank.com/#organization" }, "description": "Is Becton Dickinson (BDX) a Buy or Sell today? Get the AI trade setup, key support levels, valuation and risk analysis. Updated daily.", "name": "Becton, Dickinson and Company (BDX) Stock Forecast (2026)", "@id": "https://clearank.com/stock/bdx-stock-analysis/#richSnippet", "isPartOf": { "@id": "https://clearank.com/stock/bdx-stock-analysis/#webpage" }, "image": { "@id": "https://clearank.com/wp-content/uploads/2026/09/bdx-stock-analysis-2026-09.png" }, "inLanguage": "en-US", "mainEntityOfPage": { "@id": "https://clearank.com/stock/bdx-stock-analysis/#webpage" } } ] }, { "@context": "https://schema.org", "@type": "FinancialProduct", "name": "Becton, Dickinson and Company (BDX)", "tickerSymbol": "BDX", "url": "https://clearank.com/stock/bdx-stock-analysis/", "description": "AI-powered financial analysis for Becton, Dickinson and Company (BDX) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.", "exchange": "NYSE", "offers": { "@type": "Offer", "price": 176.42, "priceCurrency": "USD", "availability": "https://schema.org/InStock", "url": "https://clearank.com/stock/bdx-stock-analysis/", "priceValidUntil": "2026-09-12" } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is Becton, Dickinson and Company's (BDX) current consensus rating?", "acceptedAnswer": { "@type": "Answer", "text": "Becton, Dickinson and Company (BDX) currently holds a 'Hold' consensus rating from Wall Street analysts. This is based on a breakdown of 1 Strong Buy, 6 Buy, and 7 Hold ratings among the 14 analysts covering the stock." } }, { "@type": "Question", "name": "What is the upside potential for Becton, Dickinson and Company (BDX) stock based on analyst targets?", "acceptedAnswer": { "@type": "Answer", "text": "The median analyst price target for Becton, Dickinson and Company (BDX) is $197.50, suggesting an upside potential of 11.9% from its current price of $176.42." } }, { "@type": "Question", "name": "Are Becton, Dickinson and Company (BDX) insiders buying or selling stock?", "acceptedAnswer": { "@type": "Answer", "text": "Insiders at Becton, Dickinson and Company (BDX) are net sellers of the stock. Total insider sales amounted to $4.2 million, while total purchases were $1 million, resulting in a moderate sell signal." } }, { "@type": "Question", "name": "What are the key risks facing Becton, Dickinson and Company (BDX)?", "acceptedAnswer": { "@type": "Answer", "text": "Key risks for Becton, Dickinson and Company (BDX) include moderate insider selling and a significant slowdown in revenue growth, with current quarter estimates showing a 13.00% year-over-year decline. These factors could impact future profitability and stock performance." } }, { "@type": "Question", "name": "How is Becton, Dickinson and Company (BDX) performing technically?", "acceptedAnswer": { "@type": "Answer", "text": "Technically, Becton, Dickinson and Company (BDX) shows oversold conditions with an RSI of 28.46, and is trading above its 50-day and 200-day moving averages. However, it is currently below its 20-day EMA, indicating some near-term weakness." } }, { "@type": "Question", "name": "What is the revenue growth outlook for Becton, Dickinson and Company (BDX)?", "acceptedAnswer": { "@type": "Answer", "text": "The revenue growth outlook for Becton, Dickinson and Company (BDX) is currently challenged, with current quarter estimates projecting a 13.00% year-over-year decline. The next year's growth is estimated at a modest +2.00%." } }, { "@type": "Question", "name": "Is Becton, Dickinson and Company (BDX) stock a buy right now?", "acceptedAnswer": { "@type": "Answer", "text": "Becton, Dickinson and Company (BDX) is currently rated a 'Hold' by Wall Street analysts, with a median price target of $197.50, implying an 11.9% upside. While technically oversold, concerns around revenue slowdown and insider selling suggest caution." } } ] } ] }